Juniper Biologics adalengeza lero kuti wapeza ufulu wopereka chilolezo kuti apange ndi kugulitsa TG-C LD (TissueGene-C low dose) pofuna kuchiza matenda a mawondo osteoarthritis.
Chigwirizano cha $ 600 miliyoni cha USD chomwe chimakhudza Asia Pacific, Middle East ndi Africa chinasaina ndi Kolon Life Science ndipo ndi kugula kwachiwiri kwa Juniper Biologics m'miyezi ingapo. Pansi pa mgwirizano, Juniper Biologics adzakhala ndi udindo wopanga ndi kugulitsa TG-C LD kwa akatswiri azachipatala ndi zipatala m'maderawa. Kolon Life Science idzakhala ndi udindo wothandizira chitukuko komanso kupereka TG-C LD.
TG-C LD ndi chithandizo chosachita opaleshoni chofufuza chomwe chadziwika kuti ndi njira yoyamba padziko lonse lapansi yochizira matenda a nyamakazi ya bondo, [i] yomwe ndi yofala kwambiri ya nyamakazi.[ii] Malinga ndi kafukufuku, osteoarthritis akuyerekezedwa kukhala khumi ndi chimodzi[1] omwe amayambitsa kulumala padziko lonse lapansi ndi odwala pafupifupi 300 miliyoni ku Asia Pacific ndi Middle East ndi Africa kokha, akuvutika ndi zotsatira zofooketsa za matenda olowa m'malo olumikizana. Ndi chimodzi mwazofunikira kwambiri zachipatala pakati pa matenda a minofu ndi mafupa omwe ali ndi chiopsezo chowonjezeka ndi zaka[iii].
Njira yoyamba yothandizira ma cell-mediated gene therapy, TG-C LD imayang'ana nyamakazi ya bondo kudzera mu jekeseni imodzi ya intra-articular. Kolon TissueGene, yemwe ali ndi chiphatso cha TG-C ku United States (osati TG-C LD), wamaliza kale kuyesa kwachipatala kwa gawo lachiwiri ku United States, ndi chidziwitso choyambirira chosonyeza kupumula kosalekeza komanso kusintha kwakuyenda motsatira jekeseni imodzi. bondo, kwa zaka 2. Mayesero azachipatala a Phase 2 ku United States okhala ndi odwala 3 akupitilira kutsimikizira chitetezo ndi mphamvu ya TG-C. Kuwonjezera pa kutsimikizira kuchepetsa kupweteka kwa chiwerengero ndi kusintha kwa ntchito komwe kunachitika kuchokera ku mayesero achipatala a US Phase 1,020, mayeserowa apangidwa kuti awonetse kuchedwa kwa matenda kuti akwaniritse DMOAD (Disease Modifying Osteoarthritis Drug).
Mtsogoleri wamkulu wa Juniper Biologics, Raman Singh, adati: "Nthawi zonse timayang'ana kuti tidziwe madera omwe tingasinthire kwambiri ndipo TG-C LD imapereka chithandizo chambiri kwa odwala osteoarthritis a mawondo omwe angafunikire opaleshoni kapena njira zina zothandizira. Tadzipereka kupereka chithandizo chamakono pochiza nyamakazi ya bondo kudzera mu kusinthika kwa cartilage ndipo tikukhulupirira kuti chithandizo chamakono chofufuzachi chibweretsa mpumulo kwa odwala mamiliyoni ambiri mdera lonselo. "
"Ndife okondwa kugwira ntchito ndi Juniper Biologics kukhazikitsa njira zatsopano zothandizira odwala kuti athe kupeza chithandizo chamakono chofufuza ma cell. Izi zitha kukhala kutsimikizika kwaukadaulo wathu komanso mtengo wake wamsika, "atero Purezidenti wa Woosok Lee ndi CEO, Kolon Life Science. "Tikukhulupirira kuti odwala ku Asia Pacific, Middle East ndi Africa azitha kupindula ndi TG-C LD pamene tikuyenda movutikira kukhazikitsa ngati njira yothandizira padziko lonse lapansi."
